Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $33.2 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 65.76% year-over-year to $33.2 million; the TTM value through Sep 2025 reached $129.2 million, up 187.07%, while the annual FY2024 figure was $60.0 million, 44.22% down from the prior year.
  • Change in Acquisitions & Divestments reached $33.2 million in Q3 2025 per STOK's latest filing, roughly flat from $33.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $79.0 million in Q3 2022 and bottomed at $9.0 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $30.4 million, with a median of $27.2 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 491.67% in 2023, then tumbled 81.22% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $18.0 million in 2022, then dropped by 16.8% to $15.0 million in 2023, then soared by 100.0% to $30.0 million in 2024, then rose by 10.5% to $33.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $33.2 million in Q3 2025, $33.2 million in Q2 2025, and $32.8 million in Q1 2025.